Condition : Rheumatoid Arthritis Intervention : Drug: tocilizumab [RoActemra/Actemra] Sponsor : Hoffmann-La Roche Recruiting - verified February 2014

Condition : Rheumatoid Arthritis Intervention : Drug: tocilizumab [RoActemra/Actemra] Sponsor : Hoffmann-La Roche Recruiting - verified November 2013

Condition : Rheumatoid Arthritis Intervention : Sponsor : Hoffmann-La Roche Completed - verified February 2014

Condition : Juvenile Idiopathic Arthritis Intervention : Drug: tocilizumab [RoActemra/Actemra] Sponsor : Hoffmann-La Roche Completed - verified February 2014

Condition : Juvenile Idiopathic Arthritis Intervention : Drug: tocilizumab [RoActemra/Actemra] Sponsor : Hoffmann-La Roche Completed - verified November 2013

Condition : Rheumatoid Arthritis Intervention : Sponsor : Hoffmann-La Roche Completed - verified November 2013

Condition : Juvenile Idiopathic Arthritis Intervention : Drug: tocilizumab [RoActemra/Actemra] Sponsors : Hoffmann-La Roche; Hoffmann-La Roche Completed - verified September 2013

Condition : Rheumatoid Arthritis Intervention : Sponsors : Hoffmann-La Roche; Hoffmann-La Roche Completed - verified September 2013

Condition : Rheumatoid Arthritis Intervention : Drug: tocilizumab [RoActemra/Actemra] Sponsors : Hoffmann-La Roche; Hoffmann-La Roche Active, not recruiting - verified September 2013

This multicenter observational study will evaluate the use of RoActemra/Actemra (tocilizumab) in monotherapy in patients with active moderate to severe rheumatoid arthritis unable to use methotrexate....